NASHVILLE, Tenn., December 8, 2014 – Sarah Cannon Research Institute (SCRI) announced today that its investigators have authored 16 clinical trial abstracts accepted for presentation during the 2014 San Antonio Breast Cancer Symposium. The symposium, which will be held in San Antonio, Texas Dec. 9-13, brings together more than 7,500 physicians and researchers from more than 90 countries to provide state-of-the-art information on the prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.
“SCRI has long been a leader in providing novel therapies to breast cancer patients,” said Howard A. “Skip” Burris, MD, Chief Medical Officer and Executive Director, Drug Development. “We look forward to discussing the results of our research with the top breast cancer specialists as we work together to advance therapies.”
Accepted presentations include two oral sessions, four poster discussions and 10 posters. The research being presented highlights the investigation of targeted treatments for advanced breast cancers in women such as HER 2 positive and triple negative breast cancers.
In addition to Dr. Burris, other investigators representing SCRI include: Hendrik-Tobias Arkenau, MD, PhD, Director, Drug Development Program Sarah Cannon Research UK, John D. Hainsworth MD, Chief Scientific Officer, Erika P. Hamilton, MD, Associate Director, Breast Cancer Research Program, Jeffrey R. Infante, MD, Director, Drug Development Program, Suzanne Jones, PharmD, Scientific Director, Drug Development Program, and Denise A. Yardley, MD, Senior Investigator, Breast Cancer Research Program.
SCRI network affiliates presenting are: John G. Barton, Jr. MD, Lowell L. Hart, MD, William N. Harwin, MD, Carla Kurkjian, MD, Manish R. Patel, MD, Robyn R. Young, MD and the late Eric L. Raefsky, MD.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 600 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US. Please click here to earn more about our research offerings.